Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 10, 2007, Pages 3605-3611

  Stearne, Lorna E T ^a,c   Goessens, Wil H F ^a   Mouton, Johan W ^a,b   Gyssens, Inge C ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFTIZOXIME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATION; BACTERIUM MUTANT; BACTEROIDES FRAGILIS; CONTROLLED STUDY; DRUG EFFICACY; ENTEROBACTER CLOACAE; FEMALE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; SKIN ABSCESS; SUPERINFECTION;

ABSCESS; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTEROIDES FRAGILIS; BACTEROIDES INFECTIONS; CEFTIZOXIME; CULTURE MEDIA; DRUG RESISTANCE, BACTERIAL; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MUTATION;

EID: 34948873106     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01486-06     Document Type: Article

References (37)

1. Bakker-Woudenberg, I. A., M. T. ten Kate, W. H. Goessens, and J. W. Mouton. 2006. Effect of treatment duration on pharmacokinetic/ pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection. Antimicrob. Agents Chemother. 50:2919-2925.
2. Berkhout, J., M. L. Van Ogtrop, P. J. van den Broek. J. A. M. van de Klundert, H. Mattie, L. G. Visser, and W. A. Craig. 1999. Pharmacodynamics of ceftriaxone against cephalosporin-sensitive and -resistant Enterobacter cloacae in vivo, abstr. 2036. Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
3. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1054-1060.
4. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10; quiz, 11-12.
5. Cunha, B. A., and J. H. Rex. 2003. Empiric therapy based on clinical syndrome, p. 18-134. In B. A. Cunha (ed.), Antibiotic essentials, 2nd ed. Physician's Press, Royal Oak, MI.
6. Cunha, B. A., P. E. Schoch, and J. H. Rex. 2003. Initial therapy of isolates pending susceptibility testing, p. 143-185. In B. A. Cunha (ed.), Antibiotic essentials, 2nd ed. Physician's Press, Royal Oak, MI.
7. Drlica, K. 2003. The mutant selection window and antimicrobial resistance. J. Antimicrob. Chemother. 52:11-17.
8. Drusano, G. L., D. E. Johnson, M. Rosen, and H. C. Standiford. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37:483-490.
9. Dunn, D. L., and R. L. Simmons. 1984. The role of anaerobic bacteria in intraabdominal infections. Rev. Infect. Dis. 6:S139-S146.
10. Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, K. Drlica, Y. A. Portnoy, and S. H. Zinner. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1604-1613.
11. Geroulanos, S., K. Marathias, J. Kriaras, and B. Kadas. 2001. Cephalosporins in surgical prophylaxis. J. Chemother. 13:23-26.
12. Goessens, W. H. F., J. W. Mouton, M. ten Kate, A. Ott, and I. A. J. M. Bakker-Woudenberg. 2007. Role of ceftazidime dose regimen on the selection of resistant Enterobacter cloacae in the intestinal flora of rats treated for experimental pulmonary infection. J. Antimicrob. Chemother. 59:507-516.
13. Goossens, H., M. Ferech, R. Van der Stichele, M. Elseviers, and the ESAC Project Group. 2005. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365:579-587.
14. Guillemot, D., C. Carbon, B. Balkau, P. Geslin, H. Lecoeur, F. Vauzelle-Kervroedan, G. Bouvenot, and E. Eschwège. 1998. Low dosage and long treatment duration of beta-lactam. Risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 279:365-370.
15. Harbarth, S., M. H. Samore, D. Lichtenberg, and Y. Carmeli. 2000. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 101:2916-2921.
16. Kronvall, G., G. Kahlmeter, E. Myhre, and M. F. Galas. 2003. A new method for normalized interpretation of antimicrobial resistance from disc test results for comparative purposes. Clin. Microbiol. Infect. 9:120-132.
17. Lu, T., X. Zhao, X. Li, G. Hansen, J. Blondeau, and K. Drlica. 2003. Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus. J. Antimicrob. Chemother. 52:61-64.
18. Mimoz, O., S. Leotard, A. Jacolot, C. Padoin, K. Louchahl, O. Petitjean, and P. Nordman. 2000. Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing β-lactamase-producing strain of Enterobacter cloacae. Antimicrob. Agents Chemother. 44:885-890.
19. Mouton, J. W., M. N. Dudley, O. Cars, H. Derendorf, and G. L. Drusano. 2002. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int. J. Antimicrob. Agents 19:355-358.
20. Mouton, J. W., and A. A. Vinks. 1996. Is continuous infusion of beta-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations. J. Antimicrob. Chemother. 38:5-15.
21. Mouton, R. P., J. H. Glerum, and A. C. Van Loenen. 1976. Relationship between antibiotic consumption and frequence of antibiotic resistance of four pathogens - a seven year study. J. Antimicrob. Chemother. 2:9-19.
22. Murakawa, T., H. Sakamoto, S. Fukada, S. Nakamoto, T. Hirose, N. Itoh, and N. Nishida. 1980. Pharmacokinetics in animals after parenteral dosing. Antimicrob. Agents Chemother. 17:157-164.
23. Negri, M. C., M. Lipstich, J. Blazquez, B. R. Levin, and F. Baquero. 2000. Concentration-dependent selection of small phenotypic differences in TEM β-lactamase-mediated antibiotic resistance. Antimicrob. Agents Chemother. 44:2485-2491.
24. Odenholt, I., I. Gustafsson, and E. Lowdin. 2003. Postantibiotic and sub-MIC effects of benzylpenicillin against Streptococcus pneumoniae with different susceptibilities for penicillin. Chemotherapy 49:287-293.
25. Olofsson, S. K., P. Geli, D. I. Andersson, and O. Cars. 2005. Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli. Antimicrob. Agents Chemother. 49:5081-5091.
26. Pechere, J. C., and I. R. Vladoianu. 1992. Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model. J. Antimicrob. Chemother. 29:563-573.
27. Sanders, W. E., and C. C. Sanders. 1997. Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin. Microbiol. Rev. 10:220-241.
28. Soriano, F., P. Garcia-Corbeira, C. Ponte, R. Fernandez-Roblas, and I. Gadea. 1996. Correlation of pharmacodynamic parameters of five β-lactam antibiotics with therapeutic efficacies in an animal model. Antimicrob. Agents Chemother. 40:2686-2690.
29. Stearne, L. E. T., I. C. Gyssens, W. H. Goessens, J. W. Mouton, W. J. Oyen, J. W. van der Meer, and H. A. Verbrugh. 2001. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infections with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model. Antimicrob. Agents Chemother. 45:1394-1401.
30. Stearne, L. E. T., C. Kooi, W. H. Goessens, I. A. J. M. Bakker-Woudenberg, and I. C. Gyssens. 2001. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin resistant strain of Enterococcus faecium using an anaerobic time kill technique. Antimicrob. Agents Chemother. 45:243-251.
31. Stearne, L. E. T., D. van Boxtel, N. Lemmens, W. Goessens, J. W. Mouton, and I. C. Gyssens. 2004. Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacillus fragilis in vitro and in vivo in mixed-infection abscesses. Antimicrob. Agents Chemother. 48:1688-1698.
32. Tally, F. P. 1988. Factors affecting the choice of antibiotics in mixed infections. J. Antimicrob. Chemother. 22:87-100.
33. Tenover, F. C. 2001. Development and spread of bacterial resistance to antimicrobial agents: an overview. Clin. Infect. Dis. 33(Suppl 3):S108-S115.
34. Thomas, J. K., A. Forrest, S. M. Bhavnani, J. M. Hyatt, A. Cheng, C. H. Ballow, and J. J. Schentag. 1998. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob. Agents Chemother. 42:521-527.
35. Turnidge, J., G. Kahlmeter, and G. Kronvall. 2006. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cutoff values. Clin. Microbiol. Infect. 12:418-425.
36. Zhao, X., and K. Drlica. 2002. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J. Infect. Dis. 185:561-565.
37. Zinner, S. H., I. Y. Lubenko, D. Gilbert, K. Simmons, X. Zhao, K. Drlica, and A. A. Firsov. 2003. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J. Antimicrob. Chemother. 52: 616-622.